Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$328 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.6 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
6.3
Industry P/E
--
EV/EBITDA
-0
Div. Yield
0 %
Debt to Equity
0
Book Value
$1
EPS
$-0.7
Face value
--
Shares outstanding
73,246,927
CFO
$-102.13 Mln
EBITDA
$-140.14 Mln
Net Profit
$-107.12 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Candel Therapeutics Inc (CADL)
| -11.9 | -5.1 | -11.9 | -11.9 | 54.5 | -- | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Candel Therapeutics Inc (CADL)
| -34.9 | 482.0 | -17.9 | -77.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Candel Therapeutics Inc (CADL)
|
5.0 | 328.2 | 0.0 | -38.2 | -- | -64.6 | -- | 6.3 |
| 62.9 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 66.6 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 44.0 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 91.2 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 65.4 | 7,360.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.3 | 153.4 | |
| 7.1 | 6,847.2 | 113.3 | -351.4 | -211.0 | 71.1 | -- | 0.0 | |
| 529.8 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 489.5 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 319.3 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the... treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts. Address: 117 Kendrick Street, Needham, MA, United States, 02494 Read more
President, CEO & Director
Dr. Paul-Peter Tak FMEDSCI, M.D., Ph.D.
President, CEO & Director
Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.
Headquarters
Needham, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Candel Therapeutics Inc (CADL) is $4.98 (NASDAQ) as of 01-Apr-2026 16:29 EDT. Candel Therapeutics Inc (CADL) has given a return of 54.51% in the last 3 years.
Since, TTM earnings of Candel Therapeutics Inc (CADL) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-7.84
|
5.77
|
|
2024
|
-5.03
|
4.19
|
|
2023
|
-1.12
|
3.34
|
|
2022
|
-2.76
|
1.09
|
|
2021
|
-4.11
|
2.32
|
The 52-week high and low of Candel Therapeutics Inc (CADL) are Rs 7.25 and Rs 4.25 as of 02-Apr-2026.
Candel Therapeutics Inc (CADL) has a market capitalisation of $ 328 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Candel Therapeutics Inc (CADL), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.08
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.